We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02840149
Recruitment Status : Unknown
Verified February 2021 by Gad Abikhzer, Jewish General Hospital.
Recruitment status was:  Enrolling by invitation
First Posted : July 21, 2016
Last Update Posted : February 9, 2021
Information provided by (Responsible Party):
Gad Abikhzer, Jewish General Hospital

Brief Summary:
Positron emission tomography/computed tomography (PET/CT) is an advanced nuclear medicine scan. This technology allows precise and early cancer to be visualized and measured on whole body images. Patients with Neuro-Endocrine tumors (NETs), require specialized molecular imaging to stage, re-stage and assess eligibility and response to therapy. 68Ga-DOTATATE is a nuclear medicine imaging agent that is not yet approved by Health Canada but used extensively throughout the world. The Ki-67 index, a marker of cell proliferation in NETs, is one of the most important prognostic factors in this disease. The objective of this study is to evaluate if the maximal standard uptake value (SUVmax) on PET/CT in NETs inversely correlates with Ki-67 score on initial biopsy. If this hypothesized correlation between SUV and Ki-67 score is reproduced, then DOTATATE would serve as a non-invasive method to assess cellular proliferation and therefore prognosis of these patients.

Condition or disease Intervention/treatment Phase
Neuroendocrine Tumors Drug: 68Ga-DOTATATE PET/CT Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Correlation Between SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
68Ga-DOTATATE PET/CT scan performed on Neuro-endocrine tumor patients

Primary Outcome Measures :
  1. Correlation between SUV on 68Ga-DOTATATE PET/CT with Ki-67 index in NET [ Time Frame: 2 years ]
    To determine whether there is an inverse correlation between SUV on 68Ga-DOTATATE PET/CT with Ki-67 index in patients with neuroendocrine tumors

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Known or suspected somatostatin receptor positive tumor such as: neuroendocrine tumor (carcinoid, gastro-entero-pancreatic neuroendocrine tumors, etc); pheochromocytoma; neuroblastoma; medulloblastoma; ectopic Cushing syndrome/non-pituitary ACTH elevation; tumor-induced osteomalacia. Supporting evidence may include MRI, CT, biochemical markers, and/or pathology report.
  • Previous diagnosis of NET with Ki-67 index available or soon to be obtained.
  • ECOG performance status 0 - 3, inclusive.
  • 18 years or older and able to understand and provide written informed consent
  • Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan including lying supine for up to 45 minutes with the arms above the head and tolerating intravenous cannulation for injection of the study drug

Exclusion Criteria:

  • Medically unstable patients (e.g. acute cardiac or respiratory distress or hypotensive, etc.)
  • Patients who exceed the safe weight limit or bore of the PET/CT bed
  • Patients who are claustrophobic or pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02840149

Layout table for location information
Canada, Quebec
Jewish General Hospital
Montréal, Quebec, Canada, H4R3E8
Sponsors and Collaborators
Jewish General Hospital
Layout table for investigator information
Principal Investigator: Gad Abikhzer, MDCM McGill University Health Centre, Jewish General Hospital
Principal Investigator: Stephan Probst, MDCM Jewish General Hospital
Layout table for additonal information
Responsible Party: Gad Abikhzer, MD, Jewish General Hospital
ClinicalTrials.gov Identifier: NCT02840149    
Other Study ID Numbers: CODIM-MDM-16-211
First Posted: July 21, 2016    Key Record Dates
Last Update Posted: February 9, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gad Abikhzer, Jewish General Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Endocrine Gland Neoplasms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms by Site
Endocrine System Diseases